This paper is in the following e-collection/theme issue:

Non-Randomized Studies (funded, non-eHealth) (167)

Published on in Vol 5, No 3 (2016): Jul-Sept

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

Authors of this article:

Angela E Rankine-Mullings1 Author Orcid Image ;   Courtney R Little2 Author Orcid Image ;   Marvin E Reid3 Author Orcid Image ;   Deanne P Soares3 Author Orcid Image ;   Carolyn Taylor-Bryan3 Author Orcid Image ;   Jennifer M Knight-Madden1 Author Orcid Image ;   Susan E Stuber2 Author Orcid Image ;   Asha V Badaloo3 Author Orcid Image ;   Karen Aldred1 Author Orcid Image ;   Margaret E Wisdom-Phipps1 Author Orcid Image ;   Teresa Latham2 Author Orcid Image ;   Russell E Ware2 Author Orcid Image
Article Authors Cited by (9) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.